Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by StableGenius97on Jan 12, 2021 5:32pm
169 Views
Post# 32278931

Leah Gibson

Leah GibsonOut of curiousity what exactly has our star IR employee done in the past 10 months that has brought value to shareholders and the company. I checked out her LinkedIn page today and it says that she does the following

"Investor Relations and strategic communications professional in the biopharmaceuticals industry; Expertise in cultivating and retaining long-term investors and quality research analyst coverage, developing and communicating effective environmental, sustainability and governance (ESG) initiatives, and proxy management and solicitation"

Expertise in cultivating and retaining long term investors and quality research analyst coverage?
Give me a f****** break that is such a load of s***. There has been 0 coverage of this stock besides
the junk that we already had. What value is she adding to justify the salary she is getting. And dont
tell me she updated the investors presentation. You can hire a level 1 consultant to do that for 20$/hr


<< Previous
Bullboard Posts
Next >>